文献速递胸部肿瘤放疗放疗物理与技术

哪些非小细胞肺癌患者从放化疗后辅助度伐利尤单抗获益最大?一项探索性分析

Who Benefits the Most From Adjuvant Durvalumab After Chemoradiotherapy for Non-small Cell Lung Cancer? An Exploratory Analysis.
PubMed 文献 · Pract Radiat Oncol · 2020-10-27

探索性分析发现放疗后中性粒细胞与淋巴细胞比值(NLR)可能修饰度伐利尤单抗的获益。

要点

  • 辅助度伐利尤单抗与PFS和OS显著改善相关。
  • 放疗后NLR超过队列中位值4.3时,度伐利尤单抗未显示显著PFS获益。
  • 放疗后NLR<4.3的患者接受度伐利尤单抗与PFS改善相关。

核心结论

  • 放化疗后低NLR可能是与辅助度伐利尤单抗获益相关的因素,需验证研究。

研究设计与样本

  • 单中心回顾性分析纳入2013年8月至2019年5月接受根治性同步放化疗的非小细胞肺癌患者105例。

主要发现

  • 心脏和食管高平均放疗剂量与放疗后高NLR相关。

关键数值与推荐

  • 放疗后NLR中位值为4.3,作为探索性分析的分组界值。

临床怎么用

  • 对于局部晚期非小细胞肺癌同步放化疗后考虑辅助度伐利尤单抗时,可关注放疗后NLR以辅助风险分层。
  • 心脏和食管放疗剂量与放疗后NLR相关,提示放疗计划优化可能影响免疫治疗获益。

局限性

  • 为单中心回顾性探索性分析,样本量有限,结果需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Adjuvant durvalumab is now recommended for most patients with locally advanced non-small cell lung cancer after concurrent chemoradiotherapy. Herein, we explore the clinical factors that may be associated with the benefit from adjuvant durvalumab. METHODS AND MATERIALS: Patients with non-small cell lung cancer who were treated with definitive concurrent chemoradiotherapy at our institution between August 2013 and May 2019 were included in this analysis. Clinical and treatment characteristics were tested for associations with progression-free survival (PFS) in Cox models. Interaction terms were added to the PFS Cox models to explore factors that may modulate the effects of adjuvant durvalumab. PFS and overall survival (OS) rates were estimated using the Kaplan-Meier method, and comparisons between patient subgroups were performed using log rank testing. RESULTS: A total of 105 patients met the eligibility criteria. Thirty-five patients (33%) received adjuvant durvalumab. Treatment with durvalumab was associated with significant improvement in PFS (1-year PFS: 67% vs 39%; log rank P = .006) and OS (1-year OS: 88% vs 76%; log rank P = .041). Exploratory analyses identified the neutrophil-to-lymphocyte ratio (NLR) after radiation therapy (RT) as a factor that may be associated with a benefit from durvalumab. For patients with post-RT NLR exceeding the cohort's median value of 4.3, receipt of adjuvant durvalumab was not associated with a significant PFS improvement (1-year PFS: 45% vs 36%; log rank P = .702). For patients with post-RT NLR <4.3, durvalumab receipt was associated with improved PFS (69% vs 41%; P = .009). High mean RT doses delivered to the heart and esophagus were associated with high post-RT NLR. CONCLUSIONS: We identified low NLR after chemoradiotherapy as a factor that may be associated with a benefit from adjuvant durvalumab. Validation studies are warranted.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ohri N, Halmos B, Bodner WR, et al. Who Benefits the Most From Adjuvant Durvalumab After Chemoradiotherapy for Non-small Cell Lung Cancer? An Exploratory Analysis. Pract Radiat Oncol. 2020. PMID: 33127337. doi:10.1016/j.prro.2020.09.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。